Humacyte Inc (NASDAQ: HUMA) on Tuesday, plunged -0.38% from the previous trading day, before settling in for the closing price of $2.62. Within the past 52 weeks, HUMA’s price has moved between $1.15 and $9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 84.68%. With a float of $125.75 million, this company’s outstanding shares have now reached $155.12 million.
Considering the fact that the conglomerate employs 220 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.94%, while institutional ownership is 39.87%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 84.68% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 3.28 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 778.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Compared to the last year’s volume of 3.73 million, its volume of 5.11 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 69.52%. Additionally, its Average True Range was 0.25.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 39.46%, which indicates a significant decrease from 77.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.68% in the past 14 days, which was lower than the 122.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.80, while its 200-day Moving Average is $4.02.
